EUVIMEDEUVIMED entdecken
Open Access

RNA-LNP–mediated in vivo prime editing corrects disease phenotypes in a mouse model of citrullinemia type I

András Tálas iD, Eleonora I Ioannidi, Yanik Weber iD, Tatjana Haenggi iD, Péter István Kulcsár, Nadia Zürcher, Erica Faccin iD, Woohyun J Moon iD, Lucas Kissling iD, Elina Andrea Villiger iD, Mai Matsushita iD, Tanja Rothgangl und 11 weitere

Science Translational Medicine · 13.05.2026 · 18 (849)

DOI: 10.1126/scitranslmed.aec7274 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 13.05.2026. Verfasst von András Tálas und 22 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Citrullinemia, Nanoparticles, Lipids, Gene Editing. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Swiss National Science Foundation, NIAID NIH HHS, Citrin Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Citrullinemia type I (CTLN1) is a severe urea cycle disorder caused by pathogenic variants in the ASS1 (argininosuccinate synthetase 1) gene, for which liver transplantation remains the only curative option. Here, we used prime editing to correct the Ass1 fold mouse model of CTLN1. Adeno-associated virus (AAV)–mediated delivery of the PE7 prime editor with an optimized prime editing guide RNA (pegRNA) achieved 71 and 54% correction of the pathogenic Ass1 mutation in hepatocytes of neonates and juveniles, respectively. Delivery of mRNA-encoded PE7 and synthetic pegRNA via lipid nanoparticles (LNPs) resulted in 24% correction after a single 3 mg kg −1 dose in neonates and 13% after three 4 mg kg −1 doses in juveniles. All treated groups showed full normalization of survival and of blood citrulline and ammonia concentrations, with restored urea cycle function and correction of natural behavior defects. Consistent with these findings, immunostaining demonstrated restoration of wild-type–like ASS1 protein localization in functionally relevant periportal and intermediate-zone hepatocytes. Editing was confined to the liver, with minimal indel formation and off-target activity and only transient elevations in liver enzymes. In a cellular reporter system, 6 of 15 recurrent human pathogenic ASS1 mutations studied, including the most common ASS1 G390R variant, were corrected with similar or higher efficiencies than Ass1 fold . These findings highlight prime editing as a precise and potentially curative treatment strategy for individuals with CTLN1 and other genetic liver diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CitrullinemiaNanoparticlesLipidsGene EditingAnimalsDisease Models, AnimalPhenotypeArgininosuccinate SynthaseHumansLiverMiceMutationHepatocytesDependovirusCitrulline

Substanzen

Argininosuccinate SynthaseLipidsCitrulline

Autor:innen und Institutionen

  • Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.
  • Division of Metabolism and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland.
  • Acuitas Therapeutics Inc., Vancouver, BC, Canada.
  • Department of Biology, Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland.
  • Division of Clinical Chemistry and Biochemistry, University Children's Hospital Zurich, Zurich, Switzerland.
  • Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

ORCID-Profile: András Tálas, Yanik Weber, Tatjana Haenggi, Erica Faccin, Woohyun J Moon, Lucas Kissling, Elina Andrea Villiger, Mai Matsushita, Paulo J C Lin, Martin Poms, Hiromi Muramatsu, Máté Vadovics, Andreas Reichmuth, Manfred Kopf, Norbert Pardi, Ying K Tam, Johannes Häberle, Gerald Schwank

Förderung

  • Swiss National Science Foundation
  • NIAID NIH HHS
  • Citrin Foundation
  • University Research Priority Programs

Zitieren

APA

Tálas, A., Ioannidi, E. I., Weber, Y., Haenggi, T., Kulcsár, P. I., Zürcher, N., Faccin, E., Moon, W. J., Kissling, L., Villiger, E. A., Matsushita, M., Rothgangl, T., Janjuha, S., Lin, P. J. C., Poms, M., Muramatsu, H., Vadovics, M., Reichmuth, A., Kopf, M., …, & Schwank, G. (2026). RNA-LNP–mediated in vivo prime editing corrects disease phenotypes in a mouse model of citrullinemia type I. Science Translational Medicine, 18(849). https://doi.org/10.1126/scitranslmed.aec7274

Vancouver

Tálas A, Ioannidi EI, Weber Y, Haenggi T, Kulcsár PI, Zürcher N, et al. RNA-LNP–mediated in vivo prime editing corrects disease phenotypes in a mouse model of citrullinemia type I. Science Translational Medicine. 2026;18(849). doi:10.1126/scitranslmed.aec7274

BibTeX
@article{Tlas2026,
  author = {Tálas, András and Ioannidi, Eleonora I and Weber, Yanik and Haenggi, Tatjana and Kulcsár, Péter István and Zürcher, Nadia and Faccin, Erica and Moon, Woohyun J and Kissling, Lucas and Villiger, Elina Andrea and Matsushita, Mai and Rothgangl, Tanja and Janjuha, Sharan and Lin, Paulo J C and Poms, Martin and Muramatsu, Hiromi and Vadovics, Máté and Reichmuth, Andreas and Kopf, Manfred and Pardi, Norbert and Tam, Ying K and Häberle, Johannes and Schwank, Gerald},
  title = {RNA-LNP–mediated in vivo prime editing corrects disease phenotypes in a mouse model of citrullinemia type I},
  journal = {Science Translational Medicine},
  year = {2026},
  volume = {18},
  number = {849},
  doi = {10.1126/scitranslmed.aec7274}
}
Kostenlos starten →